News Date: Monday, August 3, 2020 - 09:30
This special issue will provide an overview of current translational research from both human and non-human animal researchers investigating harm reduction strategies for substance use disorders (SUDs). The goal of this special issue is to highlight new and efficacious strategies to promote harm reduction in both clinical and preclinical models, and to catalyze future translational collaborations in the field. Particular topics of interest include but are not limited to nicotine-containing products such as heat-not-burn products and e-cigarettes, as well as products and strategies that reduce the incidence of opioid overdose including fentanyl test strips, safe injection sites, and safe delivery of heroin, hydromorphone, or other opioids. Another area of interest is research on other treatment outcomes associated with harm reduction across SUDs such as improved physical and/or mental health and social functioning. Regulatory-focused reports are also encouraged within this overall topic of research. We encourage submission of review articles and original research reports in these areas, including novel strategies or behavioral outcomes in clinical and preclinical models. Paired-research articles from different laboratories that are investigating similar behavioral outcomes in clinical and preclinical models are highly encouraged. If submitting paired articles, authors are also invited to submit a comment on that set of articles. Non-human animal research that is translatable to the human condition and human research that can be back-translated to a nonhuman model are encouraged. Papers addressing a variety of substances, including alcohol, marijuana, stimulants, and opiates, and their disorders, are welcome.
Researchers in this area may submit review articles or primary research reports to Experimental and Clinical Psychopharmacology to be considered for inclusion in this special issue. Manuscripts should be submitted as usual through the APA Online Submission Portal (http://pha.edmgr.com/), selecting the Harm Reduction special issue upon submission. The cover letter should indicate that the authors wish the manuscript to be considered for publication in the special issue: Utilizing translational approaches to advance harm reduction strategies for substance use disorders. All submissions will undergo our normal peer review. Manuscripts received no later than October 1, 2020 will be considered for inclusion in the special issue. During the submission process, please select the Harm Reduction issue when submitting. We strongly encourage individuals to contact the guest editors in advance with their ideas and a draft the title and abstract.
Questions or inquiries about the special issue can be directed to the Guest Editors of the issue, Cassandra Gipson, PhD, at firstname.lastname@example.org or Andrew Huhn, PhD, at email@example.com, or the Editor, William W. Stoops, PhD at William.firstname.lastname@example.org.